DOCSLIB.ORG

Correction for Morozko Et Al., PIAS1 Modulates Striatal Transcription, DNA Damage Repair, and Sumoylation with Relevance to Hunt

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Correction for Morozko Et Al., PIAS1 Modulates Striatal Transcription, DNA Damage Repair, and Sumoylation with Relevance to Hunt Correction NEUROSCIENCE Correction for “PIAS1 modulates striatal transcription, DNA Davidsonc,p, Partha S. Sarkard,q, and Leslie M. damage repair, and SUMOylation with relevance to Huntington’s Thompsona,b,e,k,m disease,” by Eva L. Morozko, Charlene Smith-Geater, Alejandro Mas Monteys, Subrata Pradhan, Ryan G. Lim, Peter Lang- aDepartment of Neurobiology and Behavior, University of California, Irvine, felder, Marketta Kachemov, Austin Hill, Jennifer T. Stocksdale, CA 92697; bDepartment of Psychiatry and Human Behavior, University of Pieter R. Cullis, Jie Wu, Joseph Ochaba, Ricardo Miramontes, California, Irvine, CA 92697; cRaymond G. Perelman Center for Cell and Anirban Chakraborty, Tapas K. Hazra, Alice Lau, Sophie St-cyr, Molecular Therapeutics, The Children’s Hospital of Philadelphia, d Iliana Orellana, Lexi Kopan, Keona Q. Wang, Sylvia Yeung, Philadelphia, PA 19104; Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555; eInstitute of Memory Impairments and Blair R. Leavitt, Jack C. Reidling, X. William Yang, Joan S. Steffan, Neurological Disorders, University of California, Irvine, CA 92697; Beverly L. Davidson, Partha S. Sarkar, and Leslie M. Thompson, fDepartment of Human Genetics, David Geffen School of Medicine at which published January 19, 2021; 10.1073/pnas.2021836118 (Proc. University of California, Los Angeles, CA 90095; gDepartment of Natl. Acad. Sci. U.S.A. 118, e2021836118). Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; hDepartment of Chemistry, University of The authors note that Jayesh A. Kulkarni and Josh Zaifman British Columbia, Vancouver, BC, Canada V6T 1Z1; iIncisive Genetics Inc., should be added to the author list between Marketta Kachemov Vancouver, BC, Canada V6A 0H9; jNanoMedicines Innovation Network, and Austin Hill. Jayesh A. Kulkarni should be credited with University of British Columbia, Vancouver, BC, Canada V6T 1Z3; kDepartment Contributed new reagents/analytical tools and Performed of Biological Chemistry, University of California, Irvine, CA 92697; lDepartment of Internal Medicine, University of Texas Medical Branch, Research. Josh Zaifman should be credited with Contributed Galveston, TX 77555; mSue and Bill Gross Stem Cell Institute, University new reagents/analytical tools and Performed Research. The of California, Irvine, CA 92697; nCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada CORRECTION corrected author line, affiliation line, and author contribu- o tions appear below. The online version has been corrected. V5Z 4H4; Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; pDepartment of Pathology and Laboratory Medicine, Eva L. Morozkoa, Charlene Smith-Geaterb, Alejandro Mas University of Pennsylvania, Philadelphia, PA 19104; and qDepartment c d e of Neuroscience and Cell Biology, University of Texas Medical Branch, Monteys , Subrata Pradhan , Ryan G. Lim , Peter Galveston, TX 77555 Langfelderf, Marketta Kachemova, Jayesh A. Kulkarnig, Josh Zaifmanh, Austin Hilli, Jennifer T. Stocksdalea, Author contributions: E.L.M., C.S-G., A.M.M., B.R.L., J.C.R., B.L.D., P.S.S., Pieter R. Cullisg,j, Jie Wuk, Joseph Ochabaa, Ricardo and L.M.T. designed research; E.L.M., C.S-G., A.M.M., S.P., M.K., J.A.K., J.Z., e l l A.H., J.T.S., P.R.C., J.O., A.C., T.K.H., A.L., S.S.-c., I.O., L.K., K.Q.W., and S.Y. Miramontes , Anirban Chakraborty , Tapas K. Hazra , performed research; J.A.K. and J.Z. contributed new reagents/analytical Alice Laub, Sophie St-cyrc, Iliana Orellanam, Lexi Kopanb, tools; E.L.M., C.S.-G., S.P., R.G.L., P.L., J.W., R.M., J.C.R., X.W.Y., and J.S.S. b e n analyzed data; E.L.M., C.S.-G., J.C.R., X.W.Y., J.S.S., and L.M.T. wrote the Keona Q. Wang , Sylvia Yeung , Blair R. Leavitt , Jack C. paper; and B.L.D., P.S.S., and L.M.T. provided resources and funding e o b,e Reidling , X. William Yang , Joan S. Steffan , Beverly L. acquisition. Published under the PNAS license. Published August 2, 2021. www.pnas.org/cgi/doi/10.1073/pnas.2112001118 PNAS 2021 Vol. 118 No. 32 e2112001118 https://doi.org/10.1073/pnas.2112001118 | 1of1 Downloaded by guest on October 1, 2021 PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease Eva L. Morozkoa,1, Charlene Smith-Geaterb,1, Alejandro Mas Monteysc, Subrata Pradhand, Ryan G. Lime, Peter Langfelderf, Marketta Kachemova, Jayesh A. Kulkarnig, Josh Zaifmanh, Austin Hilli, Jennifer T. Stocksdalea, Pieter R. Cullisg,j, Jie Wuk, Joseph Ochabaa, Ricardo Miramontese, Anirban Chakrabortyl, Tapas K. Hazral, Alice Laub, Sophie St-cyrc, Iliana Orellanam, Lexi Kopanb, Keona Q. Wangb, Sylvia Yeunge, Blair R. Leavittn, Jack C. Reidlinge, X. William Yango, Joan S. Steffanb,e, Beverly L. Davidsonc,p,2, Partha S. Sarkard,q,2, and Leslie M. Thompsona,b,e,k,m,2,3 aDepartment of Neurobiology and Behavior, University of California, Irvine, CA 92697; bDepartment of Psychiatry and Human Behavior, University of California, Irvine, CA 92697; cRaymond G. Perelman Center for Cell and Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104; dDepartment of Neurology, University of Texas Medical Branch, Galveston, TX 77555; eInstitute of Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697; fDepartment of Human Genetics, David Geffen School of Medicine at University of California, Los Angeles, CA 90095; gDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; hDepartment of Chemistry, University of British Columbia, Vancouver, BC, Canada V6T 1Z1; iIncisive Genetics Inc., Vancouver, BC, Canada V6A 0H9; jNanoMedicines Innovation Network, University of British Columbia, Vancouver, BC, Canada V6T 1Z3; kDepartment of Biological Chemistry, University of California, Irvine, CA 92697; lDepartment of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555; mSue and Bill Gross Stem Cell Institute, University of California, Irvine, CA 92697; nCentre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4; oCenter for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; pDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; and qDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555 Edited by Stephen T. Warren, Emory University School of Medicine, Atlanta, GA, and approved December 14, 2020 (received for review October 26, 2020) DNA damage repair genes are modifiers of disease onset in SUMO modified (14) and identified Protein Inhibitor of Acti- Huntington’s disease (HD), but how this process intersects with vated STAT-1 (PIAS1) as an E3 SUMO ligase that enhances associated disease pathways remains unclear. Here we evaluated SUMOylation of HTT (15). Viral miRNA-mediated knockdown the mechanistic contributions of protein inhibitor of activated (KD) of Pias1 in R6/2 striata improved behavior and molecular NEUROSCIENCE STAT-1 (PIAS1) in HD mice and HD patient-derived induced plurip- readouts associated with HD progression (16). However, the otent stem cells (iPSCs) and find a link between PIAS1 and DNA precise mechanisms affected by PIAS1 in HD are not yet defined, damage repair pathways. We show that PIAS1 is a component of nor is the role of PIAS1 in neurons known. the transcription-coupled repair complex, that includes the DNA Here we evaluated the consequences of Pias1 reduction in a damage end processing enzyme polynucleotide kinase-phosphatase HD knockin mouse model which expresses the human expanded (PNKP), and that PIAS1 is a SUMO E3 ligase for PNKP. Pias1 knock- down (KD) in HD mice had a normalizing effect on HD transcrip- Significance tional dysregulation associated with synaptic function and disease- associated transcriptional coexpression modules enriched for DNA Genetic variants in genes involved in maintenance of genomic damage repair mechanisms as did reduction of PIAS1 in HD iPSC- stability are modifiers of Huntington’s disease (HD) age of onset. derived neurons. KD also restored mutant HTT-perturbed enzymatic This study shows a connection between the E3 SUMO ligase activity of PNKP and modulated genomic integrity of several tran- PIAS1, DNA damage repair protein PNKP, and HD-associated scriptionally normalized genes. The findings here now link SUMO transcriptional dysregulation. Reduction of Pias1 in a knockin modifying machinery to DNA damage repair responses and tran- HD mouse striatum normalizes disease-associated aberrant scriptional modulation in neurodegenerative disease. transcription, rescues perturbed enzymatic activity of Pnkp, and increases genomic integrity, while also having transcriptional DNA damage repair | SUMO | PIAS | Huntington’s disease | PNKP effects in WT animals. PIAS1 reduction in human iPSC neurons alters transcription of synaptic signaling and DNA damage re- ’ untington s disease (HD) is a devastating genetic neurode- pair, rescues PNKP activity, and increases genomic integrity in Hgenerative disease caused by an expanded CAG repeat HD iPSC-derived neurons. Finally, PIAS1 can modulate SUMO within the HD gene (HTT), which is translated into an expanded modification of PNKP, which is the first identification of an en- polyglutamine (PolyQ) repeat within the Huntingtin (HTT) zyme that regulates this modification. protein (1, 2). The size of the repeat expansion inversely corre- lates with age of onset in HD patients, with CAG-repeat length Author contributions: E.L.M., C.S-G., A.M.M., B.R.L., J.C.R., B.L.D., P.S.S., and L.M.T. de- accounting for about 50% of the observed age of onset (2, 3). signed research; E.L.M., C.S-G., A.M.M., S.P., M.K., J.A.K., J.Z., A.H., J.T.S., P.R.C., J.O., A.C., T.K.H., A.L., S.S.-c., I.O., L.K., K.Q.W., and S.Y.
Load more

Recommended publications
  • Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease
    International Journal of Molecular Sciences Review Recent Advances in Drosophila Models of Charcot-Marie-Tooth Disease Fukiko Kitani-Morii 1,2,* and Yu-ichi Noto 2 1 Department of Molecular Pathobiology of Brain Disease, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan 2 Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-75-251-5793 Received: 31 August 2020; Accepted: 6 October 2020; Published: 8 October 2020 Abstract: Charcot-Marie-Tooth disease (CMT) is one of the most common inherited peripheral neuropathies. CMT patients typically show slowly progressive muscle weakness and sensory loss in a distal dominant pattern in childhood. The diagnosis of CMT is based on clinical symptoms, electrophysiological examinations, and genetic testing. Advances in genetic testing technology have revealed the genetic heterogeneity of CMT; more than 100 genes containing the disease causative mutations have been identified. Because a single genetic alteration in CMT leads to progressive neurodegeneration, studies of CMT patients and their respective models revealed the genotype-phenotype relationships of targeted genes. Conventionally, rodents and cell lines have often been used to study the pathogenesis of CMT. Recently, Drosophila has also attracted attention as a CMT model. In this review, we outline the clinical characteristics of CMT, describe the advantages and disadvantages of using Drosophila in CMT studies, and introduce recent advances in CMT research that successfully applied the use of Drosophila, in areas such as molecules associated with mitochondria, endosomes/lysosomes, transfer RNA, axonal transport, and glucose metabolism.
    [Show full text]
  • Human DNA Glycosylase NEIL1's Interactions with Downstream
    Biomolecules 2012, 2, 564-578; doi:10.3390/biom2040564 OPEN ACCESS biomolecules ISSN 2218-273X www.mdpi.com/journal/biomolecules/ Article Human DNA Glycosylase NEIL1’s Interactions with Downstream Repair Proteins Is Critical for Efficient Repair of Oxidized DNA Base Damage and Enhanced Cell Survival Muralidhar L. Hegde 1,2, Pavana M. Hegde 1, Dutta Arijit 1, Istvan Boldogh 3 and Sankar Mitra 1,* 1 Department of Biochemistry and Molecular Biology, University of Texas Medical Branch (UTMB) at Galveston, Texas 77555-1079, USA; E-Mails: [email protected] (M.L.H.); [email protected] (P.M.H.); [email protected] (D.A.) 2 Department of Neurology, University of Texas Medical Branch (UTMB) at Galveston, Texas 77555, USA 3 Department of Microbiology and Immunology, University of Texas Medical Branch (UTMB) at Galveston, Texas 77555, USA; E-Mail: [email protected] (I.B.) * Author to whom correspondence should be addressed; E-Mail: [email protected] (S.M.); Tel.: +1-409-772-1780; Fax: +1-409-747-8608. Received: 15 October 2012; in revised form: 7 November 2012 / Accepted: 9 November 2012 / Published: 15 November 2012 Abstract: NEIL1 is unique among the oxidatively damaged base repair-initiating DNA glycosylases in the human genome due to its S phase-specific activation and ability to excise substrate base lesions from single-stranded DNA. We recently characterized NEIL1’s specific binding to downstream canonical repair and non-canonical accessory proteins, all of which involve NEIL1’s disordered C-terminal segment as the common interaction domain (CID). This domain is dispensable for NEIL1’s base excision and abasic (AP) lyase activities, but is required for its interactions with other repair proteins.
    [Show full text]
  • Modulation of STAT Signaling by STAT-Interacting Proteins
    Oncogene (2000) 19, 2638 ± 2644 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Modulation of STAT signaling by STAT-interacting proteins K Shuai*,1 1Departments of Medicine and Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes Interaction with non-STAT transcription factors including immune responses, cell growth and dierentia- tion, cell survival and apoptosis, and oncogenesis. In Studies on the promoters of a number of IFN-a- contrast to many other cellular signaling cascades, the induced genes identi®ed a conserved DNA sequence STAT pathway is direct: STATs bind to receptors at the named ISRE (interferon-a stimulated response element) cell surface and translocate into the nucleus where they that mediates IFN-a response (Darnell, 1997; Darnell function as transcription factors to trigger gene activa- et al., 1994). Stat1 and Stat2, the ®rst known members tion. However, STATs do not act alone. A number of of the STAT family, were identi®ed in the transcription proteins are found to be associated with STATs. These complex ISGF-3 (interferon-stimulated gene factor 3) STAT-interacting proteins function to modulate STAT that binds to ISRE (Fu et al., 1990, 1992; Schindler et signaling at various steps and mediate the crosstalk of al., 1992). ISGF-3 consists of a Stat1:Stat2 heterodimer STATs with other cellular signaling pathways. This and a non-STAT protein named p48, a member of the article reviews the roles of STAT-interacting proteins in IRF (interferon regulated factor) family (Levy, 1997).
    [Show full text]
  • Mediated Repair of Transcribed Genes Is Linked to SCA3 Pathogenesis
    Deficiency in classical nonhomologous end-joining– mediated repair of transcribed genes is linked to SCA3 pathogenesis Anirban Chakrabortya, Nisha Tapryala, Tatiana Venkovaa,1, Joy Mitrab, Velmarini Vasquezb, Altaf H. Sarkerc, Sara Duarte-Silvad,e, Weihan Huaif, Tetsuo Ashizawag, Gourisankar Ghoshf, Patricia Macield,e, Partha S. Sarkarh, Muralidhar L. Hegdeb, Xu Cheni, and Tapas K. Hazraa,2 aDepartment of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Medical Branch, Galveston, TX 77555; bDepartment of Neurosurgery, Center for Neuroregeneration, The Houston Methodist Research Institute, Houston, TX 77030; cDepartment of Cancer and DNA Damage Responses, Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720; dSchool of Medicine, Life and Health Sciences Research Institute, University of Minho, 4710-057 Braga, Portugal; eICVS (Life and Health Sciences Research Institute)/3B’s-PT Government Associate Laboratory, 4710-057 Braga/Guimarães, Portugal; fDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093; gDepartment of Neurology, The Houston Methodist Research Institute, Houston, TX 77030; hDepartment of Neurology and Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555; and iDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093 Edited by James E. Cleaver, University of California San Francisco Medical Center, San Francisco, CA, and approved March 2, 2020 (received for review October 6, 2019) Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited ATXN3 knockout mice showed an increase in total ubiquitinated neurodegenerative disease caused by CAG (encoding glutamine) protein levels (19). Consistently, knockdown of ATXN3 resulted in repeat expansion in the Ataxin-3 (ATXN3) gene.
    [Show full text]
  • Downloaded from As a Tab-Delimited file, in Which Genes Are Represented in Rows and Phenotypes in Columns
    cells Article Network of Interactions between ZIKA Virus Non-Structural Proteins and Human Host Proteins 1, 1,2, 2 Volha A. Golubeva y , Thales C. Nepomuceno y , Giuliana de Gregoriis , Rafael D. Mesquita 3, Xueli Li 1, Sweta Dash 1,4, Patrícia P. Garcez 5 , Guilherme Suarez-Kurtz 2 , Victoria Izumi 6, John Koomen 7, Marcelo A. Carvalho 2,8,* and Alvaro N. A. Monteiro 1,* 1 Cancer Epidemiology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; [email protected] (V.A.G.); [email protected] (T.C.N.); xueli.li@moffitt.org (X.L.); sweta.dash@moffitt.org (S.D.) 2 Divisão de Pesquisa Clínica, Instituto Nacional de Câncer, Rio de Janeiro 20230-130, Brazil; [email protected] (G.d.G.); [email protected] (G.S.-K.) 3 Departamento de Bioquímica, Instituto de Química, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Brazil; [email protected] 4 Cancer Biology PhD Program, University of South Florida, Tampa, FL 33612, USA 5 Institute of Biomedical Science, Federal University of Rio de Janeiro, Rio de Janeiro 20230-130, Brazil; [email protected] 6 Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; victoria.izumi@moffitt.org 7 Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; john.koomen@moffitt.org 8 Instituto Federal do Rio de Janeiro-IFRJ, Rio de Janeiro 20270-021, Brazil * Correspondence: [email protected] (M.A.C.); alvaro.monteiro@moffitt.org (A.N.A.M.); Tel.: +55-21-2566-7774 (M.A.C.); +813-7456321 (A.N.A.M.) These authors contributed equally to this work.
    [Show full text]
  • The Dark Side of UV-Induced DNA Lesion Repair
    G C A T T A C G G C A T genes Review The Dark Side of UV-Induced DNA Lesion Repair Wojciech Strzałka 1, Piotr Zgłobicki 1, Ewa Kowalska 1, Aneta Ba˙zant 1, Dariusz Dziga 2 and Agnieszka Katarzyna Bana´s 1,* 1 Department of Plant Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland; [email protected] (W.S.); [email protected] (P.Z.); [email protected] (E.K.); [email protected] (A.B.) 2 Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-12-664-6410 Received: 27 October 2020; Accepted: 29 November 2020; Published: 2 December 2020 Abstract: In their life cycle, plants are exposed to various unfavorable environmental factors including ultraviolet (UV) radiation emitted by the Sun. UV-A and UV-B, which are partially absorbed by the ozone layer, reach the surface of the Earth causing harmful effects among the others on plant genetic material. The energy of UV light is sufficient to induce mutations in DNA. Some examples of DNA damage induced by UV are pyrimidine dimers, oxidized nucleotides as well as single and double-strand breaks. When exposed to light, plants can repair major UV-induced DNA lesions, i.e., pyrimidine dimers using photoreactivation. However, this highly efficient light-dependent DNA repair system is ineffective in dim light or at night. Moreover, it is helpless when it comes to the repair of DNA lesions other than pyrimidine dimers.
    [Show full text]
  • Monitoring Regulation of DNA Repair Activities of Cultured Cells In-Gel Using the Comet Assay
    REVIEW ARTICLE published: 16 July 2014 doi: 10.3389/fgene.2014.00232 Monitoring regulation of DNA repair activities of cultured cells in-gel using the comet assay Catherine M. Nickson and Jason L. Parsons* Department of Molecular and Clinical Cancer Medicine, North West Cancer Research Centre, University of Liverpool, Liverpool, UK Edited by: Base excision repair (BER) is the predominant cellular mechanism by which human cells Andrew Collins, University of Oslo, repair DNA base damage, sites of base loss, and DNA single strand breaks of various Norway complexity, that are generated in their thousands in every human cell per day as a Reviewed by: consequence of cellular metabolism and exogenous agents, including ionizing radiation. Antonella Sgura, University of Roma Tre, Italy Over the last three decades the comet assay has been employed in scientific research Nathan Ellis, University of Arizona, to examine the cellular response to these types of DNA damage in cultured cells, USA therefore revealing the efficiency and capacity of BER. We have recently pioneered new Andrew Collins, University of Oslo, Norway research demonstrating an important role for post-translational modifications (particularly ubiquitylation) in the regulation of cellular levels of BER proteins, and that subtle changes *Correspondence: Jason L. Parsons, Department of (∼20–50%) in protein levels following siRNA knockdown of E3 ubiquitin ligases or Molecular and Clinical Cancer deubiquitylation enzymes can manifest in significant changes in DNA repair capacity Medicine, North West Cancer monitored using the comet assay. For example, we have shown that the E3 ubiquitin ligase Research Centre, University of Liverpool, 200 London Road, Mule, the tumor suppressor protein ARF,and the deubiquitylation enzyme USP47 modulate Liverpool L3 9TA, UK DNA repair by controlling cellular levels of DNA polymerase β, and also that polynucleotide e-mail: [email protected] kinase phosphatase levels are controlled by ATM-dependant phosphorylation and Cul4A– DDB1–STRAP-dependent ubiquitylation.
    [Show full text]
  • Cell Culture-Based Profiling Across Mammals Reveals DNA Repair And
    1 Cell culture-based profiling across mammals reveals 2 DNA repair and metabolism as determinants of 3 species longevity 4 5 Siming Ma1, Akhil Upneja1, Andrzej Galecki2,3, Yi-Miau Tsai2, Charles F. Burant4, Sasha 6 Raskind4, Quanwei Zhang5, Zhengdong D. Zhang5, Andrei Seluanov6, Vera Gorbunova6, 7 Clary B. Clish7, Richard A. Miller2, Vadim N. Gladyshev1* 8 9 1 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard 10 Medical School, Boston, MA, 02115, USA 11 2 Department of Pathology and Geriatrics Center, University of Michigan Medical School, 12 Ann Arbor, MI 48109, USA 13 3 Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, 14 MI 48109, USA 15 4 Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 16 48109, USA 17 5 Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10128, USA 18 6 Department of Biology, University of Rochester, Rochester, NY 14627, USA 19 7 Broad Institute, Cambridge, MA 02142, US 20 21 * corresponding author: Vadim N. Gladyshev ([email protected]) 22 ABSTRACT 23 Mammalian lifespan differs by >100-fold, but the mechanisms associated with such 24 longevity differences are not understood. Here, we conducted a study on primary skin 25 fibroblasts isolated from 16 species of mammals and maintained under identical cell culture 26 conditions. We developed a pipeline for obtaining species-specific ortholog sequences, 27 profiled gene expression by RNA-seq and small molecules by metabolite profiling, and 28 identified genes and metabolites correlating with species longevity. Cells from longer-lived 29 species up-regulated genes involved in DNA repair and glucose metabolism, down-regulated 30 proteolysis and protein transport, and showed high levels of amino acids but low levels of 31 lysophosphatidylcholine and lysophosphatidylethanolamine.
    [Show full text]
  • Distinct E€Ects of PIAS Proteins on Androgen-Mediated Gene Activation
    Oncogene (2001) 20, 3880 ± 3887 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Distinct eects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells Mitchell Gross1, Bin Liu1, Jiann-an Tan3, Frank S French3, Michael Carey2 and Ke Shuai*,1,2 1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, CA 90095, USA; 2Department of Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA; 3The Laboratories for Reproductive Biology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, NC 27599-7500, USA Androgen signaling in¯uences the development and The androgen receptor (AR) is a member of the growth of prostate carcinoma. The transcriptional nuclear receptor (NR) superfamily (Bentel and Tilley, activity of androgen receptor (AR) is regulated by 1996). NRs have conserved domain structures (Freed- positive or negative transcriptional cofactors. We report man, 1999). At the N-terminus is the ligand- here that PIAS1, PIAS3, and PIASy of the protein independent transcriptional activation domain (AF- inhibitor of activated STAT (PIAS) family, which are 1). The central domain contains two zinc ®nger expressed in human prostate, display distinct eects on structures that are involved in DNA binding (DBD). AR-mediated gene activation in prostate cancer cells. The C-terminal region is the ligand binding domain While PIAS1 and PIAS3 enhance the transcriptional (LBD). In addition, an essential ligand-dependent activity of AR, PIASy acts as a potent inhibitor of AR transactivation domain (AF-2) is localized in the C- in prostate cancer cells.
    [Show full text]
  • A Molecular Quantitative Trait Locus Map for Osteoarthritis
    ARTICLE https://doi.org/10.1038/s41467-021-21593-7 OPEN A molecular quantitative trait locus map for osteoarthritis Julia Steinberg 1,2,3,4, Lorraine Southam1,3, Theodoros I. Roumeliotis3,5, Matthew J. Clark 6, Raveen L. Jayasuriya6, Diane Swift6, Karan M. Shah 6, Natalie C. Butterfield 7, Roger A. Brooks8, Andrew W. McCaskie8, J. H. Duncan Bassett 7, Graham R. Williams 7, Jyoti S. Choudhary 3,5, ✉ ✉ J. Mark Wilkinson 6,9,11 & Eleftheria Zeggini 1,3,10,11 1234567890():,; Osteoarthritis causes pain and functional disability for over 500 million people worldwide. To develop disease-stratifying tools and modifying therapies, we need a better understanding of the molecular basis of the disease in relevant tissue and cell types. Here, we study primary cartilage and synovium from 115 patients with osteoarthritis to construct a deep molecular signature map of the disease. By integrating genetics with transcriptomics and proteomics, we discover molecular trait loci in each tissue type and omics level, identify likely effector genes for osteoarthritis-associated genetic signals and highlight high-value targets for drug development and repurposing. These findings provide insights into disease aetiopathology, and offer translational opportunities in response to the global clinical challenge of osteoarthritis. 1 Institute of Translational Genomics, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany. 2 Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia. 3 Wellcome Sanger Institute, Hinxton, United Kingdom. 4 School of Public Health, The University of Sydney, Sydney, NSW, Australia. 5 The Institute of Cancer Research, London, United Kingdom. 6 Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
    [Show full text]
  • PIAS1 Potentiates the Anti-EBV Activity of SAMHD1 Through Sumoylation
    Saiada et al. Cell Biosci (2021) 11:127 https://doi.org/10.1186/s13578-021-00636-y Cell & Bioscience RESEARCH Open Access PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation Farjana Saiada1, Kun Zhang1 and Renfeng Li1,2,3* Abstract Background: Sterile alpha motif and HD domain 1 (SAMHD1) is a deoxynucleotide triphosphohydrolase (dNTPase) that restricts the infection of a variety of RNA and DNA viruses, including herpesviruses. The anti-viral function of SAMHD1 is associated with its dNTPase activity, which is regulated by several post-translational modifcations, includ- ing phosphorylation, acetylation and ubiquitination. Our recent studies also demonstrated that the E3 SUMO ligase PIAS1 functions as an Epstein-Barr virus (EBV) restriction factor. However, whether SAMHD1 is regulated by PIAS1 to restrict EBV replication remains unknown. Results: In this study, we showed that PIAS1 interacts with SAMHD1 and promotes its SUMOylation. We identifed three lysine residues (K469, K595 and K622) located on the surface of SAMHD1 as the major SUMOylation sites. We demonstrated that phosphorylated SAMHD1 can be SUMOylated by PIAS1 and SUMOylated SAMHD1 can also be phosphorylated by viral protein kinases. We showed that SUMOylation-defcient SAMHD1 loses its anti-EBV activity. Furthermore, we demonstrated that SAMHD1 is associated with EBV genome in a PIAS1-dependent manner. Conclusion: Our study reveals that PIAS1 synergizes with SAMHD1 to inhibit EBV lytic replication through protein– protein interaction and SUMOylation. Keywords: SAMHD1, PIAS1, Restriction factor, Epstein-Barr virus, Cytomegalovirus, SUMOylation, Herpesvirus, Deoxynucleotide triphosphohydrolase, Phosphorylation Background and human simplex virus 1 (HSV-1) [2–7], vaccinia virus Host restriction factors serve as the frst line of defense [2], human T cell leukemia virus type 1 [8], hepatitis B against viral infection through blocking virus entry, virus [9] and human papillomavirus 16 [10].
    [Show full text]
  • Complex-Based Analysis of Dysregulated Cellular Processes In
    Complex-based analysis of dysregulated cellular processes in cancer Sriganesh Srihari∗1, Piyush B. Madhamshettiwar1, Sarah Song1, Chao Liu1, Peter T. Simpson2, Kum Kum Khanna3, and Mark A. Ragan∗1 1Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia. 2The University of Queensland Centre for Clinical Research, Brisbane, Queensland 4006, Australia. 3QIMR-Berghofer Institute of Medical Research, Brisbane, Queensland 4006, Australia. Email: SS1∗– [email protected]; PBM – [email protected]; SS2 – [email protected]; CL – [email protected]; PTS – [email protected]; KKK – [email protected]; MAR∗– [email protected]; ∗Corresponding author Abstract Background: Differential expression analysis of (individual) genes is often used to study their roles in diseases. However, diseases such as cancer are a result of the combined effect of multiple genes. Gene products such as proteins seldom act in isolation, but instead constitute stable multi-protein complexes performing dedicated functions. Therefore, complexes aggregate the effect of individual genes (proteins) and can be used to gain a better understanding of cancer mechanisms. Here, we observe that complexes show considerable changes in their expression, in turn directed by the concerted action of transcription factors (TFs), across cancer conditions. arXiv:1408.1177v1 [q-bio.MN] 6 Aug 2014 We seek to gain novel insights into cancer mechanisms through a systematic analysis of complexes and their transcriptional regulation. Results: We integrated large-scale protein-interaction (PPI) and gene-expression datasets to identify complexes that exhibit significant changes in their expression across different conditions in cancer.
    [Show full text]